Abbott Laboratories Q1 2024 Results Summary
Business Context and Reporting Period
Abbott Laboratories (ABT) filed a Form 8-K on April 17, 2024, to announce its results of operations for the first quarter of 2024. The filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release for these figures but does not include the data within the 8-K body text itself.
Material Changes and Non-GAAP Measures
Abbott utilizes non-GAAP financial measures to assess performance, adjusting for unusual or unpredictable items. These adjustments include:
- Expenses related to acquisitions, restructuring, and cost reduction initiatives.
- Fair value adjustments to contingent consideration from business acquisitions.
- Impairment charges on intangible assets or equity investments.
- Certain regulatory costs and tax benefits associated with specified items.
- Net tax expense from resolving prior-year tax positions.
- Excess tax benefits from share-based compensation.
- Intangible amortization expense.
The filing does not quantify the specific impact of these items or the magnitude of changes versus the prior period.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook statements, or detailed risk factors beyond the standard caution that non-GAAP measures should not substitute for GAAP measures. Management states these non-GAAP measures are used internally to monitor business performance and provide visibility on ongoing operations.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2024 revenue, net earnings, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of excluded items.
- Confirm specific details on restructuring costs and acquisition-related expenses mentioned in the non-GAAP adjustments.
- Check for updated full-year guidance provided in the referenced press release.